Please login to the form below

Not currently logged in
Email:
Password:

Sutro Biopharma hires chief business officer and VP research

Dr Jeremy Bender and Dr Aaron Sato join as company prepares to advance antibody development

Sutro Biopharma has appointed Dr Jeremy Bender as chief business officer and Dr Aaron Sato as VP, research, as it prepares to advance development of its cancer antibodies.

Dr Bender joins from Allos Therapeutics, where he was VP, corporate development, responsible for mergers and acquisitions, financing transactions, product in-and out-licensing and strategic planning.

During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.

He was also heavily involved in the acquisition of Allos by Spectrum Pharmaceuticals.

Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior director of antibody engineering.

Prior to this, Dr Sato held director positions at Dyax, where he oversaw multiple external collaborations with major pharmaceutical companies.

"Dr Bender's broad skill set in corporate business development and strategic collaborations will help us maximise the select business opportunities we are actively pursuing,” said William Newell, CEO of Sutro.

“Dr Sato's expertise in antibody and protein engineering and phage display driven discovery is important to Sutro's design and development of next-generation antibody drug conjugates and bifunctional antibody-based therapeutics."

26th October 2012

From: Research

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consult

Consult is a bespoke data collection service designed to support marketing research clients in meeting those changing, increasingly focused research...

Latest intelligence

England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....
Pharma deal watch - handshake
Pharma deals during March 2014
Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month...